Aprea Therapeutics
14
1
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
21.4%
3 terminated/withdrawn out of 14 trials
72.7%
-13.8% vs industry average
7%
1 trials in Phase 3/4
113%
9 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Study of APR-1051 in Patients With Advanced Solid Tumors
Role: lead
Study Of ATRN-119 In Patients With Advanced Solid Tumors
Role: lead
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Role: lead
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Role: lead
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Role: lead
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Role: lead
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Role: lead
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Role: lead
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Role: lead
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Role: lead
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Role: collaborator
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
Role: collaborator
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Role: lead
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
Role: lead
All 14 trials loaded